Alloy Therapeutics UK Ltd Cambridge £45,000 – £50,000 pa
Design and build large-scale synthetic gene loci and transgenic platforms for antibody discovery, using CRISPR/Cas9, RMCE and site-specific integrases. Hands-on molecular biology including PCR, NGS, plasmid construction and flow-cytometric immunophenotyping, within a small multidisciplinary team working from dry-lab design to wet-lab validation.
NanoFCM CO., LTD Stevenage £26,000 – £40,000 pa
Field-based role installing, maintaining and servicing nano-flow cytometry instruments at customer sites across the UK and Europe, plus remote phone and email troubleshooting of hardware, software and reagents. Involves preventative maintenance scheduling, service documentation, spare parts inventory and coordinating service contracts with the sales team, following training with senior technical staff.
Bluetree Cambridge £65,000 – £80,000 pa
Lead regulatory strategy for a cardiology device company expanding into the US, UK, EU and Middle East, owning FDA, CE and UKCA submissions from Class I to Class II/III. Drive an audit-ready QMS (ISO 13485, 21 CFR Part 820, ISO 14971) and advise senior leadership on regulation, quality and clinical governance, working directly with the FDA, MHRA and notified bodies.
Ellison Institute of Technology Oxford £40,000 pa
Develops and optimises LC-MS workflows for low-input and single-cell proteomics and/or metabolomics, supporting researchers across the institute with experiment design, method development, data acquisition and interpretation. Works closely with bioinformatics, scientific computing and AI/ML teams, and helps build SOPs and training material for single-cell MS capability.
CSL Maidenhead US$212,000 – US$251,000 pa
Leads the full statistical contribution to a clinical development programme, defining statistical strategy for trial design, analysis and regulatory submissions, and representing Biostatistics in interactions with the FDA, EMA and PMDA. Also manages outsourcing to CROs/FSPs and contributes to governance and development-plan decisions across therapeutic areas.
